Castle Biosciences Inc
NASDAQ:CSTL
Castle Biosciences Inc
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.
AdvanceAD-Tx Launch: Castle Biosciences announced the launch of AdvanceAD-Tx, a new test for guiding systemic treatment in moderate to severe atopic dermatitis, targeting a $33 billion US opportunity.
Strong Revenue Growth: Q3 revenue reached $83 million, and full-year 2025 revenue guidance was raised to $327–335 million, up from the previous $310–320 million range.
Test Volume Milestones: Both DecisionDx-Melanoma and TissueCypher tests exceeded 10,000 report volumes in a quarter for the first time; DecisionDx-Melanoma reports grew 12% YoY, TissueCypher 75% YoY.
Margins & Profitability: Gross margin declined to 74.7% from 79.2% YoY. The company posted a net loss of $0.5 million versus net income of $2.3 million last year.
Reimbursement & SCC: SCC test LCD reconsideration requests were accepted by Medicare contractors; timing and outcome remain uncertain, but clinicians continue to order the test.
Cash Position: Ended Q3 with $287.5 million in cash, cash equivalents, and marketable securities, and expects to deliver positive net cash flow from operations for 2025.
